AR099798A1 - METHODS AND COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT - Google Patents

METHODS AND COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT

Info

Publication number
AR099798A1
AR099798A1 ARP150100832A ARP150100832A AR099798A1 AR 099798 A1 AR099798 A1 AR 099798A1 AR P150100832 A ARP150100832 A AR P150100832A AR P150100832 A ARP150100832 A AR P150100832A AR 099798 A1 AR099798 A1 AR 099798A1
Authority
AR
Argentina
Prior art keywords
antigen binding
bispecific antibodies
certain embodiments
present application
antibodies
Prior art date
Application number
ARP150100832A
Other languages
Spanish (es)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR099798A1 publication Critical patent/AR099798A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente solicitud proporciona anticuerpos biespecíficos que se enlazan a CD3 y antígenos de tumor y métodos de uso del mismo. De acuerdo con ciertas modalidades, los anticuerpos biespecíficos de la solicitud exhiben funciones efectoras reducidas y tienen un perfil de enlace único con respecto a los receptores Fcy. Los anticuerpos biespecíficos están diseñados para inducir eficazmente la muerte de células T mediadas por las células tumorales. De acuerdo con ciertas modalidades, la presente solicitud proporciona moléculas de enlace al antígeno biespecíficos que comprenden un primer dominio de enlace al antígeno que se enlaza específicamente al CD3 humano, una segunda molécula de enlace al antígeno que se enlaza específicamente a CD20 humano, y un dominio Fc que se enlaza a receptores Fcy con un específico patrón de enlace. En ciertas modalidades, las moléculas de enlace al antígeno biespecíficos de la presente solicitud son capaces de inhibir el crecimiento de tumores de células B o de melanoma que expresan CD20. Los anticuerpos biespecíficos de la solicitud son útiles para el tratamiento de varios tipos de cáncer, así como otras enfermedades y trastornos relacionados con CD20.The present application provides bispecific antibodies that bind to CD3 and tumor antigens and methods of use thereof. According to certain embodiments, the bispecific antibodies of the application exhibit reduced effector functions and have a unique binding profile with respect to Fcy receptors. Bispecific antibodies are designed to effectively induce the death of T cells mediated by tumor cells. In accordance with certain embodiments, the present application provides bispecific antigen binding molecules that comprise a first antigen binding domain that specifically binds to human CD3, a second antigen binding molecule that specifically binds to human CD20, and a Fc domain that binds to Fcy receptors with a specific binding pattern. In certain embodiments, the bispecific antigen binding molecules of the present application are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the application are useful for the treatment of various types of cancer, as well as other diseases and disorders related to CD20.

ARP150100832A 2014-03-19 2015-03-19 METHODS AND COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT AR099798A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461955663P 2014-03-19 2014-03-19

Publications (1)

Publication Number Publication Date
AR099798A1 true AR099798A1 (en) 2016-08-17

Family

ID=58699943

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100832A AR099798A1 (en) 2014-03-19 2015-03-19 METHODS AND COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT

Country Status (3)

Country Link
AR (1) AR099798A1 (en)
HR (1) HRP20210615T1 (en)
MA (2) MA50374B1 (en)

Also Published As

Publication number Publication date
HRP20210615T1 (en) 2021-05-28
MA50374A (en) 2020-01-15
MA50374B1 (en) 2021-06-30
MA39751B1 (en) 2019-11-29

Similar Documents

Publication Publication Date Title
MX2020004410A (en) Antibody compositions for tumor treatment.
CL2020003179A1 (en) (application divisional 713-2015) anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20; and uses thereof.
CO2018001485A2 (en) Bispecific monovalent diabodies that are capable of binding to b7 - h3 and cd3
CY1122840T1 (en) HUMANIZED OR CHIMERIC CD3 ANTIBODIES
CY1124787T1 (en) ANTI-GITR ANTIBODIES AND METHODS OF USING THEM
ECSP18043564A (en) BI-SPECIFIC MOLECULES THAT HAVE IMMUNOREACTIVITY WITH PD-1 AND CTLA-4, AND METHODS OF USE OF THE SAME
CO2018000887A2 (en) Bispecific antibody constructs that bind to egfrviii and cd3
EA201790719A1 (en) BISPECIFIC MONOVALENT DIATELS, WHICH ARE CAPABLE TO BIND CD19 AND CD3, AND THEIR APPLICATION THEREOF
CL2017001154A1 (en) Specific binding molecules for CD73 and uses thereof
AR107442A1 (en) ANTIBODIES AGAINST THE ORPHANE RECEPTOR SIMILAR TO THE THIROSINE QUINASE 1 (ANTI-ROR1) RECEPTOR, BISPECIFIC ANTIBODIES THAT JOIN ROR1 AND THE CD3 ANTIGEN, AND METHODS FOR TREATMENT OF CANCER
EA201790060A1 (en) BISPECIFIC CD33- and CD3-BINDING PROTEINS
EA201691824A1 (en) ANTIBODIES AGAINST EGFRVIII AND THEIR APPLICATIONS
EA201791554A1 (en) BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20
BR112016030740A2 (en) bispecific heterodimeric bodies and their uses
EA201690447A1 (en) BISPECIFIC MONOVALENT DIATELS, WHICH ARE CAPABLE OF CONNECTING WITH gpA33 AND CD3, AND THEIR APPLICATION
CO7160093A2 (en) Anti-egfr antibodies and uses thereof
TN2016000046A1 (en) Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof
PH12020551689A1 (en) Her2-targeting antigen binding molecules comprising 4-1bbl
EA201490717A1 (en) ANTIBODIES TO ErbB3 AND THEIR APPLICATION
EA201792581A1 (en) METHODS OF APPLICATION OF BISPECIFIC CD33- and CD3-BINDING PROTEINS
MX2015008534A (en) ANTI- INTEGRIN ß1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF.
CO6630177A2 (en) Compositions and methods for the diagnosis and treatment of tumors
AR099798A1 (en) METHODS AND COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT
EA202090303A2 (en) COMPOSITIONS OF ANTIBODIES FOR TREATMENT OF TUMORS
AR121863A2 (en) BIESPECIFIC CD33 AND CD3-BINDING PROTEINS